Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndromes: early-phase trial registry
73 of 193 indexed Myelodysplastic Syndromes trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #55 of 28,707 conditions by registered trial count.
193 US clinical trials · 73 currently recruiting · #55 of 28,707 conditions by registered trial count
Myelodysplastic Syndromes: 193 US clinical trials tracked, 73 recruiting.
Myelodysplastic Syndromes is the subject of 193 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 13 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndromes
OPEN 73 | RECR 38% | LATE 11 | EARLY 148 | RANK #55 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Myelodysplastic Syndromes lists 73 open slots (38% of 193 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndromes recruits in line with its size-band peers.
73 of 193 indexed trials (37.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myelodysplastic Syndromes trials is spread across many organizations.
Washington University School of Medicine accounts for 13 of 193 trials (6.7%). 98 distinct sponsors appear on at least one study for this condition label.
-
Most Myelodysplastic Syndromes trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 174 trials that report a genuine target (sentinel values excluded). 118 of those (67.8%) plan for fewer than 100 participants.
-
Myelodysplastic Syndromes research is mostly interventional.
177 interventional and 16 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
193 total, page 4 of 4
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
NCT01065129
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Dartmouth-Hitchcock Medical Center
NCT00789256
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
Washington University School of Medicine
NCT00384956
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Washington University School of Medicine
NCT00986804
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
NCT00624936
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts
H. Lee Moffitt Cancer Center and Research Institute
NCT00624585
Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00004263
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University School of Medicine
NCT00875745
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
NCT04055844
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
NCT03393611
Experimental Bone Marrow Transplant Protocol
National Heart, Lung, and Blood Institute (NHLBI)
NCT00061581
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT00002832
Amifostine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00003048
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT05024994
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT00526292
Bortezomib in Treating Patients With Myelodysplastic Syndromes
University of Rochester
NCT00262873
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00301951
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT04151706
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
NCT00005092
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
NCT00304018
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
NCT00005988
A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
NYU Langone Health
NCT03433781
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
NCT00003661
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00003959
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00014469
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Drexel University College of Medicine
NCT00003619
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Northwestern University
NCT00004896
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
NCT00002502
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
NCT00019656
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
NCT00004232
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
NCT00064311
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
Fallon Clinic
NCT00053001
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00005804
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University School of Medicine
NCT00003107
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
University of Michigan Rogel Cancer Center
NCT00005598
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00006098
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Memorial Sloan Kettering Cancer Center
NCT00006040
Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT00014482
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
University of Wisconsin, Madison
NCT00052832
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
NCT00006083
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
University of Maryland, Baltimore
NCT00015951
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00006042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndromes page
193 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Myelodysplastic Syndromes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Myelodysplastic Syndromes trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndromes condition card totals 193 registered trials; most-linked intervention Azacitidine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.